Myocardial Reperfusion Injury - Complications
Research News and Information

Monday, November 23, 2009

Ranolazine, an antianginal agent, markedly reduces ventricular arrhythmias induced by ischemia and ischemia-reperfusion.

16 Sep 2009 We tested the effect of the antianginal agent ranolazine on ventricular arrhythmias in an ischemic model using two protocols. In protocol 1, anesthetized rats received either vehicle or ranolazine (10 mg/kg, iv bolus) and were subjected to 5 min of ... Read more...

Activation of Akt/GSK-3beta signaling pathway is involved in intermedin(1-53) protection against myocardial apoptosis induced by ischemia/reperfusion.

30 Aug 2009 Intermedin (IMD) is a novel member of the calcitonin/calcitonin gene-related peptide family. We investigated the cardioprotective mechanism of IMD(1-53) in the in vivo rat model of myocardial ischemia/reperfusion (I/R) injury and in vitro primary ... Read more...

GAP-134 ([2S,4R]-1-[2-aminoacetyl]4-benzamidopyrrolidine-2-carboxylic acid) prevents spontaneous ventricular arrhythmias and reduces infarct size during myocardial ischemia/reperfusion injury in open-chest dogs.

30 Aug 2009 The antiarrhythmic dipeptide, GAP-134, ([2S,4R]-1[2-aminoacetyl]-4-benzamido-pyrrolidine-2-carboxylic acid) was evaluated in canine ischemia/reperfusion model. In dogs subjected to 60-minute ischemia and 4-hour reperfusion, GAP-134 was administered ... Read more...

Latest indexed articles for 'Myocardial Reperfusion Injury - Complications'

These are the very latest articles for this heading:

• Ranolazine, an antianginal agent, markedly reduces ventricular arrhythmias induced by ischemia and ischemia-reperfusion. 16 Sep 2009
• Activation of Akt/GSK-3beta signaling pathway is involved in intermedin(1-53) protection against myocardial apoptosis induced by ischemia/reperfusion. 30 Aug 2009
• GAP-134 ([2S,4R]-1-[2-aminoacetyl]4-benzamidopyrrolidine-2-carboxylic acid) prevents spontaneous ventricular arrhythmias and reduces infarct size during myocardial ischemia/reperfusion injury in open-chest dogs. 30 Aug 2009
• Ischemia and reperfusion-induced arrhythmias: role of hyperoxic preconditioning. 30 Jul 2009
• Comparison of isoflurane-, sevoflurane-, and desflurane-induced pre- and postconditioning against myocardial infarction in mice in vivo. 11 Jul 2009
• Protection against in vivo focal myocardial ischemia/reperfusion injury-induced arrhythmias and apoptosis by hesperidin. Jul 2009
• Dysfunction induced by ischemia versus edema: does edema matter? 29 Jun 2009
• [Significance of opioid receptors in regulation of cardiac tolerance in pathogenic impact of long-term ischemia-reperfusion in vivo] 30 May 2009
• Parecoxib inhibits apoptosis in acute myocardial infarction due to permanent coronary ligation but not due to ischemia-reperfusion. 30 May 2009
• Cryptotanshinone, a lipophilic compound of Salvia miltiorrriza root, inhibits TNF-alpha-induced expression of adhesion molecules in HUVEC and attenuates rat myocardial ischemia/reperfusion injury in vivo. May 2009
• Cardiac ischemia and reperfusion in spontaneously diabetic rats with and without application of EGb 761: II. Interstitium and microvasculature. 29 Apr 2009
• BAY 58-2667, a nitric oxide-independent guanylyl cyclase activator, pharmacologically post-conditions rabbit and rat hearts. 28 Apr 2009
• Effect of thrombin fragment (TP508) on myocardial ischemia-reperfusion injury in hypercholesterolemic pigs. 14 Apr 2009
• Piceatannol, a derivative of resveratrol, moderately slows I(Na) inactivation and exerts antiarrhythmic action in ischaemia-reperfused rat hearts. Apr 2009
• Erythropoietin protects the heart from ventricular arrhythmia during ischemia and reperfusion via neuronal nitric-oxide synthase. 21 Mar 2009
• Small animal models of heart failure: development of novel therapies, past and present. 27 Feb 2009
• Modulation of cardioprotective effect of ischemic pre- and postconditioning in the hyperhomocysteinemic rat heart. 27 Feb 2009
• Thrombin fragment (TP508) decreases myocardial infarction and apoptosis after ischemia reperfusion injury. 27 Feb 2009
• The T wave: is it the Traffic light of cardiac disorders or the Troublemaker of rhythmology? 26 Feb 2009
• The cannabinoid receptor type 2 promotes cardiac myocyte and fibroblast survival and protects against ischemia/reperfusion-induced cardiomyopathy. 24 Feb 2009

See a longer list of these articles.

Technical information about 'Myocardial Reperfusion Injury'

Definition: Damage to the MYOCARDIUM resulting from MYOCARDIAL REPERFUSION (restoration of blood flow to ischemic areas of the HEART.) Reperfusion takes place when there is spontaneous thrombolysis, THROMBOLYTIC THERAPY, collateral flow from other coronary vascular beds, or reversal of vasospasm.

Descriptor UI: D015428

Alternative terms: Myocardial Reperfusion Injury; Injuries, Myocardial Reperfusion; Myocardial Reperfusion Injuries; Reperfusion Injuries, Myocardial; Reperfusion Injury, Myocardial; Injury, Myocardial Reperfusion; Myocardial Ischemic Reperfusion Injury;

Related Mesh Headings: Myocardial Reperfusion; Myocardial Stunning;

Allowable Qualifiers: blood; cerebrospinal fluid; chemically induced; classification; complications; congenital; diagnosis; diet therapy; drug therapy; economics; embryology; enzymology; ethnology; etiology; genetics; history; immunology; metabolism; microbiology; mortality; nursing; epidemiology; parasitology; pathology; physiopathology; prevention & control; psychology; radiography; radionuclide imaging; radiotherapy; rehabilitation; surgery; therapy; urine; veterinary; ultrasonography; virology;

Tree Number: C14.280.238.615; C14.280.647.625; C14.907.585.625; C14.907.725.600; C23.550.767.877.500;

History Note: 89